|
|
Volumn 4, Issue 6, 2005, Pages 441-
|
|
In this issue
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOOXYGENASE 2 INHIBITOR;
DRUG;
GLYCAN;
NATALIZUMAB;
PSYCHOTROPIC AGENT;
COST EFFECTIVENESS ANALYSIS;
CYTOLOGY;
DIAGNOSTIC VALUE;
DISEASE ASSOCIATION;
DISEASE SEVERITY;
DRUG APPROVAL;
DRUG DETERMINATION;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SCREENING;
DRUG TARGETING;
DRUG WITHDRAWAL;
ECONOMIC ASPECT;
EDITORIAL;
GLYCOBIOLOGY;
HUMAN;
HYPOTHESIS;
INFLAMMATION;
LIVER DISEASE;
MALIGNANT NEOPLASTIC DISEASE;
MENTAL DISEASE;
MULTIPLE MYELOMA;
PHARMACOGENOMICS;
POPULATION RESEARCH;
POSTMARKETING SURVEILLANCE;
PRIORITY JOURNAL;
PROCESS OPTIMIZATION;
RESOURCE ALLOCATION;
SIDE EFFECT;
|
|
EID: 85047175661
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd1772 Document Type: Editorial |
|
Times cited : (1)
|
|
References (0)
|